<DOC>
	<DOCNO>NCT01674855</DOCNO>
	<brief_summary>This study determine whether once-per-cycle DA-3031 ( PEG-G-CSF ) inferior daily G-CSF chemotherapy-induced neutropenia .</brief_summary>
	<brief_title>Phase III Study DA-3031 ( PEG-G-CSF ) Chemotherapy-induced Neutropenia</brief_title>
	<detailed_description>Eligible subject randomly assign receive once-per-cycle DA-3031 ( PEG-G-CSF ) daily G-CSF ( 10 day ) . This study conduct 6 cycle chemotherapy , cycle repeat every 21 day .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age : ≥18 , ≤70 2 . Diagnosis stage II , III IV breast cancer 3 . ANC≥1,500/mm3 , Platelet≥100,000/mm3 , ECOG : 0 1 4 . Creatinine &lt; 1.5 x ULN 5 . Total bilirubin/AST/ALT &lt; 1.5 x ULN , ALP &lt; 2.5 x ULN 6 . Have give write , inform consent 1 . Prior chemotherapy 2 . Prior bone marrow stem cell transplantation 3 . Other malignancy history within 5 year 4 . Prior exposure pegfilgrastim filgrastim colonystimulating factor 5 . Received investigational drug within 30 day inform consent date 6 . Radiation therapy within 4 week inform consent date 7 . Infective symptom chemotherapy study 8 . Received systemic antibiotic within 72 hour randomization study . 9 . HIV positive 10 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PEG-G-CSF</keyword>
</DOC>